Heterozygous familial hypercholesterolemia (HeFH)
NAMSNewAmsterdam Pharma Company NVCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Obicetrapib in Heterozygous familial hypercholesterolemia (HeFH). The expected timing is based on the latest available company guidance and may change.
BROOKLYN trial. 7/29/24– Topline data reported, met primary endpoint. Additional data in 2025. 11/05/25:- Pooled BROADWAY/BROOKLYN MACE analysis published in JACC; additional LDL particle data at AHA 2025. 02/18/26:- Additional BROOKLYN HeFH data planned in 2026; EMA/UK/Swiss approval decisions for obicetrapib expected H2 2026. 05/07/26:- ACC BROADWAY/BROOKLYN analyses showed renal benefits; more Phase 3 data through 2026; EMA/UK/Swiss approvals H2 2026; launches Q4 2026. 06/03/26:- Pooled BROADWAY/BROOKLYN MACE and integrated Ph3 safety analyses at NLA 2026 June 12. 07/24/26:- CHMP recommended Ubeslo EU marketing authorization. European Commission decision expected H2 2026. 08/05/26:- NLA analyses showed pooled MACE reduction; more BROOKLYN data expected in 2026.
Verification
Confirm timing and program details against the company announcement or filing.